Drawing for VOLTAFLEX

USPTO serial 79199996

VOLTAFLEX

Reviewed by CopyMark Law Group

Reg. 5215883Status 709
Filing date
Status date
Registration date
Jun 6, 2017
Examiner
COLEMAN, CIMMERIAN
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with VOLTAFLEX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 29, 2024INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Sep 4, 2024INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Sep 4, 2024INPCINVALIDATION PROCESSED—
Aug 23, 2024INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Dec 22, 2023C71TCANCELLED SECTION 71—
Jul 28, 2017GPNXNOTIFICATION PROCESSED BY IB—
Jul 7, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 7, 2017FIMPFINAL DISPOSITION PROCESSED—
Jul 6, 2017GPARGRANT OF PROTECTION CREATED, TO BE SENT TO IB—
Jun 6, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 21, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 17, 2017GPNXNOTIFICATION PROCESSED BY IB—
Mar 1, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 1, 2017OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 1, 2017NPUBNOTICE OF PUBLICATION—
Feb 8, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 8, 2017DOCKASSIGNED TO EXAMINER—
Jan 21, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 17, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 13, 2017LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Jan 5, 2017SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance